doc. PharmDr. Andrea Gažová, PhD.
Vedecko/umelecko-pedagogická charakteristika:
Najvýznamnejšie výstupy tvorivej činnosti: VTC1, VTC2, VTC3, VTC4, VTC5
1. | Gažová A, Leddy JJ, Rexová M, Hlivák P, Hatala R, Kyselovič J. Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). Medicine (Baltimore). 2019 | Q3 | IF 1,552 |
2. | Gazova A, Samakova A, Laczo E, Hamar D, Polakovicova M, Jurikova M, Kyselovic J. Clinical utility of miRNA-1, miRNA-29g and miRNA-133s plasma levels in prostate cancer patients with high-intensity training after androgen-deprivation therapy. Physiological Research. 2019 | Q4 | IF 1,655 |
3. | Gažová A, Valášková S, Žufková V, Castejon AM, Kyselovič J. Clinical study of effectiveness and safety of CELcomplex® containing Cucurbita Pepo Seed extract and Flax and Casuarina on stress urinary incontinence in women. Journal of Traditional and Complementary Medicine. 2018 | - | - |
4. | Krenek P, Kmecova J, Kucerova D, Bajuszova Z, Musil P, Gazova A, Ochodnicky P, Klimas J, Kyselovic J. Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function. European Journal of Heart Failure. 2009 | Q1 | IF 3,706 |
5. | Juraj M, Jaroslav V, Gažová A, Žufková V, Kyselovič J, Šteňo B. Evaluation of efficacy and safety of systemic and topical intra-articular administration of tranexamic acid in primary unilateral total hip arthroplasty. Medicine (Baltimore). 2021 | Q3 | IF 1.889 |